Canine parvovirus (CPV) remains one of the most challenging infectious diseases encountered in veterinary practice, causing significant morbidity, mortality, and financial burden for pet owners. While supportive care remains the foundation of treatment, emerging therapies are creating new opportunities to improve patient outcomes and expand clinical decision-making. In this webinar, we explore the latest evidence supporting fecal microbiota transplantation (FMT) and CPV-specific monoclonal antibody therapy, including data from recent clinical studies. Attendees will gain practical guidance on incorporating these innovative therapies into a spectrum-of-care approach that balances patient needs, clinical resources, and economic considerations.

Learning Objectives

• Review the pathophysiology of canine parvovirus infection and the limitations of current standard-of-care treatment approaches.
• Understand the mechanisms of action of fecal microbiota transplantation (FMT) and CPV-specific monoclonal antibody therapies.
• Analyze clinical trial and retrospective data evaluating the effectiveness of emerging CPV treatments.
• Learn how to incorporate FMT and monoclonal antibody therapy into a spectrum-of-care model for inpatient and outpatient cases.
• Evaluate the impact of novel CPV therapies on recovery time, hospitalization duration, clinical outcomes, and treatment costs.
• Apply practical clinical decision-making frameworks to support individualized CPV treatment plans.